Market closedADR
Haleon/$HLN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Haleon
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Ticker
$HLN
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
25,408
Website
Haleon Metrics
BasicAdvanced
$45B
61.24
$0.17
0.19
$0.16
1.04%
Price and volume
Market cap
$45B
Beta
0.19
52-week high
$10.67
52-week low
$7.89
Average daily volume
11M
Dividend rate
$0.16
Financial strength
Total debt to equity
54.175
Interest coverage (TTM)
6.26%
Management effectiveness
Valuation
Price to earnings (TTM)
61.236
Price to revenue (TTM)
6.569
Price to book
2.18
Price to tangible book (TTM)
-3.7
Dividend yield (TTM)
1.56%
Forward dividend yield
1.04%
Growth
Revenue change (TTM)
-0.65%
Earnings per share change (TTM)
-2.93%
What the Analysts think about Haleon
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Haleon stock.
Haleon Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Haleon Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Haleon News
AllArticlesVideos
Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%
Proactive Investors·3 hours ago
Haleon results could provide tonic for investor anxiety, says Barclays
Proactive Investors·2 days ago
Haleon to invest $54 mln in US R&D centre to boost product innovation
Reuters·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Haleon stock?
Haleon (HLN) has a market cap of $45B as of February 27, 2025.
What is the P/E ratio for Haleon stock?
The price to earnings (P/E) ratio for Haleon (HLN) stock is 61.24 as of February 27, 2025.
Does Haleon stock pay dividends?
Yes, the Haleon (HLN) stock pays dividends to shareholders. As of February 27, 2025, the dividend rate is $0.15798 and the yield is 1.04%. Haleon has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Haleon dividend payment date?
The next Haleon (HLN) dividend payment date is unconfirmed.
What is the beta indicator for Haleon?
Haleon (HLN) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.